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Background: Preeclampsia is a hypertensive disorder of pregnancy that is characterized by the development of elevated 
blood pressure and proteinuria after 20 weeks of conception in a previously normotensive and non‑proteinuric patient. It is 
one of the leading and most important causes of maternal and perinatal morbidity and mortality and it occurred in about 6% 
of human pregnancies. In Usmanu Danfodiyo Teaching Hospital Sokoto, preeclampsia and its complications were the leading 
causes of death in the year 2016. Preeclampsia has many suggested biomarkers, some of which are not well‑defined. It has 
been assumed that failure in trophoblastic invasion and induction of an inflammatory process within the placenta in patients 
with preeclampsia may trigger the expression of CA‑125 antigen. This study established a definite association between 
CA‑125 and preeclampsia.
Aims: This study was conducted to determine the relationship between cancer antigen 125 and preeclampsia and its 
correlation with severity.
Settings and Design: Hospital‑based study, comparative cross‑sectional study.
Methods and Materials: Ninety‑seven pregnant women with preeclampsia were recruited as cases while 97 pregnant women 
without preeclampsia were similarly recruited as controls. In both groups (cases and controls), only women with singleton 
pregnancies at ≥32 weeks’ gestational ages were recruited. Sociodemographic characteristics, obstetric history, family history, 
and clinical data were obtained using a standard interviewer‑administered questionnaire. Anthropometric measurements 
were taken. Blood samples were taken for measurement of serum cancer antigen 125. Mean arterial pressure (MAP) was 
used as an indicator of the severity of the disease.
Statistical Analysis Used: SPSS computer statistical software version 22, percentages, Chi‑square, mean, Pearson 
correlation test.
Results: The age range of the respondents was between 16 and 45 years. The mean age for the control was 
28.6 ± 5.9 years, 27.9 ± 7.5 and 28.7 ± 7.2 years, for the control and severe preeclampsia groups, respectively. The 
mean level of CA‑125 in the preeclampsia group was significantly higher than the control (36.13 ± 23.02 vs 24.53 ± 9.42). 
The mean levels of CA‑125 in severe preeclampsia were significantly higher than mild preeclampsia (45.68 ± 23.38 
vs 21.94 ± 13.18), P = 0.001. The MAP in mild and 
severe preeclampsia was 112.82 ± 3.55 mmHg and 
130.63 ± 12.87 mmHg respectively. A negligible positive 
correlation was observed between the MAP and CA‑125 
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Introduction
Preeclampsia is a leading cause of maternal and perinatal 




in a 24-h urine collection) first occurring after 20 weeks of 
gestation.[1,2] Preeclampsia is severe when systolic blood 
pressure	is	≥160	mmHg	systolic	or	≥110	mmHg	diastolic,	
urine protein excretion is greater than 5 g in a 24-h collection, 
and neurologic disturbances.[2] Other criteria include 
pulmonary edema, hepatic dysfunction, renal compromise, 
thrombocytopenia, placental abruption, and fetal growth 
restriction.[1,2]
While its etiology is not completely clear,[3] risk factors include 
nulliparity, previous history of preeclampsia in multiparas, 
maternal age, race, familial aggregation, and socioeconomic 
status.[4-7]
Cancer antigen 125 (CA-125) is an inflammatory mediator 
which is located on the cell surface.[8,9] It is generally 
expressed in ovarian cancer,[10] endometriosis, fibroids, pelvic 
inflammatory disease, and pregnancy.[8] It is theorized that 
the failure of trophoblastic invasion and the induction of an 
inflammatory process within the placenta may trigger the 
expression of CA-125.[8,9,11]
This study examined the association of CA-125 and 
preeclampsia.
Subjects and Methods
A comparative cross-sectional study was conducted. 
Ninety-seven pregnant women with preeclampsia were 
recruited as cases and 97 pregnant women without 
preeclampsia were similarly recruited as controls. 
Sociodemographic characteristics, obstetric history, family 
history, and clinical data were obtained using a standard 
interviewer-administered questionnaire. Anthropometric 
measurements were taken and blood samples were taken 
for measurement of serum cancer antigen 125. Mean arterial 
pressure (MAP) was used as an indicator of the severity of 
preeclampsia. The data obtained were analyzed using mean, 
t-test and Pearson correlation test. Approval from the ethics 
committee was obtained 27-03-2017.
Results
The 194 study participants were recruited into three groups: 
Control (n = 97), mild preeclampsia (n = 39), and severe 
preeclampsia (n = 58).
Table 1 shows the demographic characteristics of the 
patients. The age range of the respondents was between 16 
and 45 years. The mean age for the control was 28.6 ± 5.9, 
for the mild preeclampsia group, it was 27.9 ± 7.5 while for 
the severe preeclampsia group, it was 28.7 ± 7.2. 50.8% of 
the preeclamptics and 49.2% of the controls made up the 
married population. Most of the study respondents had 
either primary 67 (34.5%) or secondary education 87 (44.8%).
Table 2 shows mean systolic and diastolic blood pressure of 
the control group were lower than the study group (113.92 
± 10.56mmHg vs 162.16 ± 18.44mmHg), and (69.28 ± 8.37 
mmHg vs  104.12 ± 12.81mmHg) respectively.
Discussion
Table 3 shows the highest MAP of 130.63 ± 12.87, with 
a range of 113–183 mmHg in the severe preeclampsia 
group.
Tables 4 and 5 show statistically significant differences 
between the mean concentrations of CA-125 in the control 
and study groups (24.53 ± 9.42 IU/mL vs 36.13 ± 23.02 IU/mL).
Using Pearson correlation test, Table 5 shows a positive 
correlation, that was statistically significant between MAP and 
CA-125 in the preeclamptic group (r =0.70, P value = 0.001).
Table 6 shows a negligible positive correlation, was observed 
between the MAP and CA-125 in the mild preeclampsia 
group (r =0.01, P value = 0.48) but, a positive correlation, 
that was statistically significant was observed between the 
MAP and CA-125 in the severe preeclampsia group (r =0.62, 
P value = 0.001). 
in the mild preeclampsia group (r = 0.01, P = 0.48), while a positive correlation, that was statistically significant was 
observed between the MAP and CA‑125 in the severe preeclampsia group (r = 0.62, P = 0.001).
Conclusions: This study found a significant association between preeclampsia and CA‑125. In addition, a positive relationship 
between the level of CA‑125 and the severity of preeclampsia was established.
Key words: CA‑125; preeclampsia; Sokoto.
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This current study showed that the age range was similar 
to what has been used by other authors.[6,7-9] The mean 
concentration of maternal serum CA-125 in normal pregnancy 
was 24.53 ± 9.42 IU/ml in this study. This is similar to 
17.2 ± 8.1 IU/mL found by Karaman et al. in normal 
pregnancy.[1] However, a higher level has been reported 
by Bhattacharya et al. who found a mean concentration 
of 47 ± 3.34 IU/mL in normal pregnancy.[9] Also, Ozat 
et al. in their own study got a mean concentration of 
48.25 ± 3.34 IU/mL in normal pregnancies.[8] A much lower 
level was reported by Miami et al. who got a mean level of 
13.70 ± 8.44 IU/mL.[7] In addition, Gyawali et al. got a mean 
level of 9.0 IU/mL.[8] The wide variations in these values could 
be due to the different kits and methods used in the assay 
of maternal serum CA-125.
The mean level of CA-125 in preeclamptic respondents 
in this study was 36.13 ± 23.02 IU/mL. A mean level of 
21.94 ± 13.18 IU/mL was observed in mild preeclamptics, 
while a mean level of 45.68 ± 23.38 IU/mL was seen in 
the severe preeclamptics in this study. This is comparable 
to a study by Karaman et al. who observed a mean 
concentration of 18.8 ± 8.4 IU/mL in mild preeclamptics, and 
38.8 ± 20.9 IU/mL in severe preeclamptics.[1] Bhattacharya 
et al. observed a mean concentration of 53.7 ± 8.52 IU/mL 
in the mild preeclampsia group, and 58.5 ± 4.02 IU/mL in 
the severe preeclampsia group.[9]
This current study established a positive relationship between 
the level of CA-125 and severity of preeclampsia, as shown 
by the increase in the mean concentrations of CA-125 in 
the severe preeclampsia group, and also the statistically 
significant positive correlation between the MAP and 
CA-125 in the preeclampsia group (r = 0.07, P = 0.001). 
This was comparable with the findings of Cereboy et al. 
that reported that CA-125 levels were significantly higher in 
severe preeclampsia compared to mild preeclampsia.[12] Also, 
significant correlations were reported between CA-125, and 
MAP in their study.[12]
Likewise, in the study conducted by Osanyin et al., serum levels 
of CA-125 were higher in severe preeclampsia as compared to 
mild forms, and CA-125 showed a significant correlation with 
blood pressure.[13] Similarly, Ozat et al. found in their own study 
that serum CA-125 concentrations were positively correlated 
with systolic blood pressure and diastolic blood pressure.[8] 
Furthermore, Karaman et al. reported in their study that CA-125 
levels were significantly higher in severe preeclampsia than 
those with mild preeclampsia and normal controls, and CA-125 
levels were positively correlated with systolic blood pressure 
and diastolic blood pressure.[1] Consistently, Miami et al. also 











<20 5 (29.4) 4 (23.5) 8 (47.1)
20‑24 21 (52.5) 12 (30.0) 7 (17.5)
25‑29 33 (62.3) 5 (9.4) 15 (28.3) 14.33 0.07
30‑34 18 (43.9) 11 (26.8) 12 (29.3)
35 and above 20 (46.5) 7 (16.3) 16 (37.2)
Total 97 (50.0) 39 (20.1) 58 (29.9)
Mean age 28.63±5.91 27.92±7.45 28.69±7.15
Educational status
None 2 (100) 0 (0.0) 0 (0.0)
Primary 21 (31.3) 20 (29.9) 26 (38.8)
Secondary 59 (67.8) 12 (13.8) 16 (18.4) 26.54 0.001
Tertiary 8 (47.1) 2 (11.8) 7 (41.2)
Quranic 7 (33.3) 5 (23.8) 9 (42.9)
Total 97 (50.0) 39 (20.1) 58 (29.9)
Occupation
Housewife 42 (39.3) 23 (21.5) 42 (39.3)
Civil servant 16 (66.7) 4 (16.7) 4 (16.7)
Trader 24 (66.7) 7 (19.4) 5 (13.9) 18.86 0.001
Student 8 (61.5) 4 (30.8) 1 (7.7)
Unemployed 7 (50.0) 1 (7.1) 6 (42.9)
Total 97 (50.0) 39 (20.1) 58 (29.9)
Table 3: MAP in both the study and the control groups
Control Mild PE Severe PE
MAP (mmHg) Mean±SD 84.16±8.052 112.82±3.55 130.63±12.87






CA‑125 (IU/mL) 24.53 (9.42) 36.13 (23.02) 4.59 0.001











CA‑125 (IU/mL) 24.53 (9.42) 21.94 (13.18) 45.68 (23.38) 0.001 0.001
Table 6: Correlation between CA-125 and map in the control 
and study groups
CA-125 (IU/mL) Control Preeclampsia
MAP (mmHg) −0.18 0.70
Control: (r=−0.18, P=0.08), study (r=0.70, P=0.001)
Table 2: Blood pressure values of study respondents




Systolic blood pressure (mmHg) 113.92 (10.56) 162.16 (18.44)
Diastolic blood pressure (mmHg) 69.28 (8.37) 104.12 (12.81)
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concluded in their study that serum CA-125 was significantly 
higher in the preeclampsia groups in comparison to the control 
group and the increment was directly correlated with the 
severity of preeclampsia.[14] In accordance, Bhattacharya et al. 
in their study found out that serum CA-125 concentrations 
were positively correlated with systolic blood pressure and 
diastolic blood pressure.[7] They concluded in their study that 
CA-125 is a biochemical marker that indicates the severity of 
the inflammatory process in preeclampsia.[7] Bon et al. reported 
in their study that maternal serum levels of CA-125 were higher 
during the first and third trimester of pregnancy, but that it 
showed no relation with preeclampsia.[15] However, of the 120 
women with pathologic pregnancies involved in their study, 
only six were preeclamptics, and this number was rather too 
small to draw conclusions. Also, the method used to detect 
serum CA-125 was the Enzymun-Test CA-125 11, which used 
the intensity of the color developed after the addition of 
substrate as proportional to the concentration of CA-125 in the 
specimen.[15] This method is observer-dependent and could be 
biased. A study carried out by Groot et al. failed to detect any 
difference between normal and preeclamptic maternal plasma 
CA-125 at any time during pregnancy.[16] However, 20 women 
were studied in all; 10 normal, and 10 preeclamptics. This 
paucity of patients may have underestimated the association 
of CA-125 with preeclampsia. Also, the criteria used to 
diagnose severe preeclampsia in their study was an increase 
in	systolic	blood	pressure	of	≥30	mmHg,	and	an	increase	in	
diastolic	blood	pressure	of	≥15	mmHg,	above	the	booking	
blood pressure. These criteria are now obsolete, and none of 
the cases met the recent criteria for the diagnosis of severe 
preeclampsia.[17-20]
Conclusion
This study observed the mean concentration of CA-125 in 
normal pregnancies to be significantly lower than the level in 
preeclamptics. Also, a positive relationship between the level 
of CA-125 and the severity of preeclampsia was established. 
Further research is required to clarify the clinical utility of 
CA-125 as a predictor of preeclampsia.
Limitation
There were significant differences in education and 
occupation of the control and study groups which may have 
affected the study outcome.
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